Comparing Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Agonist Versus Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Chinese Patients with Type 2 Diabetes Mellitus: A Preliminary Study

被引:0
作者
Wei, Yuanbo [1 ]
Ma, Huihui [2 ]
Wei, Tianshuai [3 ]
机构
[1] Xuchang Univ, Med Coll, Xuchang 461000, Henan, Peoples R China
[2] Henan Prov Peoples Hosp, Dept Endocrinol, Zhengzhou 450000, Henan, Peoples R China
[3] Yuzhou Municipal Hosp Tradit Chinese Med, Dept Imaging, Yuzhou 461670, Henan, Peoples R China
关键词
Dapagliflozin; diabetes mellitus; Dulaglutide; glucagon-like peptide-1; HbA1c; sodium-glucose cotransporter-2 inhibitor; BODY-MASS INDEX; GLYCATED HEMOGLOBIN; LIRAGLUTIDE; DULAGLUTIDE; EXENATIDE; DURATION; METAANALYSIS; MULTICENTER; PHASE-3; WEIGHT;
D O I
10.3923/ijp.2024.672.681
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective: Several selective glucagon-like peptide 1 receptor inhibitors have been developed for the treatment of Type 2 Diabetes (T2DM) but their dosing is limited by gastrointestinal adverse effects. Sodium-glucose cotransporter 2 inhibitors are approved by the USFDA for clinical use along with diet and exercise in elderly T2DM patients. The present study compared the efficacy and safety of Dulaglutide (Dula) versus Dapagliflozin in T2DM patients. Materials and Methods: Chinese T2DM patients with an age of at least 18 years with a history of poorly controlled blood glucose levels were enrolled. Subjects who met the suitability conditions were randomized to receive (1:1:1) either Dula (0.75 mg, weekly once, given subcutaneously, n = 100) or Dula (1.5 mg, weekly once, given subcutaneously, n = 100) or Dapagliflozin (10 mg daily, n = 100). Each enrolled patient was carefully monitored and followed up for 26 weeks. Results: Dula 1.5 mg had the greatest reduction in HbA1c (%) as compared to Dula 0.75 mg and Dapagliflozin. A similar trend of reduction was observed while comparing the reduction that occurred in Dapagliflozin-treated patients. Dula 0.75 mg reported a greater decrease in HbA1c levels from baseline. Dula 1.5 mg reported a greater decrease in HbA1c levels than Dapagliflozin. The incidence of gastrointestinal-related events more in Dula compared to Dapagliflozin, however, there were no serious gastrointestinal-related adverse events that led to discontinuation of Dula. Conclusion: Dula and Dapagliflozin were found effective in the management of diabetes. Glycemic control was higher in patients who received Dula, especially 1.5 mg compared to Dapagliflozin.
引用
收藏
页码:672 / 681
页数:10
相关论文
共 25 条
[1]   Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials [J].
Blonde, Lawrence ;
Chava, Pavan ;
Dex, Terry ;
Lin, Jay ;
Nikonova, Elena V. ;
Goldenberg, Ronald M. .
DIABETES OBESITY & METABOLISM, 2017, 19 (02) :275-283
[2]   Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review [J].
Boyle, James G. ;
Livingstone, Rachel ;
Petrie, John R. .
CLINICAL SCIENCE, 2018, 132 (15) :1699-1709
[3]  
Carls GS, 2017, OBES SCI PRACT, V3, P342, DOI 10.1002/osp4.116
[4]   Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial [J].
Chen, Yu Hong ;
Huang, Chien-Ning ;
Cho, Young Min ;
Li, Pengfei ;
Gu, Liqun ;
Wang, Feng ;
Yang, Jun ;
Wang, Wei Qing .
DIABETES OBESITY & METABOLISM, 2018, 20 (09) :2121-2130
[5]   Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain [J].
Conget, Ignacio ;
Mauricio, Didac ;
Ortega, Rafael ;
Detournay, Bruno .
BMJ OPEN, 2016, 6 (07)
[6]  
Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI [10.2337/dci18-0033, 10.1007/s00125-018-4729-5]
[7]   Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c [J].
Gallwitz, Baptist ;
Dagogo-Jack, Samuel ;
Thieu, Vivian ;
Garcia-Perez, Luis-Emilio ;
Pavo, Imre ;
Yu, Maria ;
Robertson, Kenneth E. ;
Zhang, Nan ;
Giorgino, Francesco .
DIABETES OBESITY & METABOLISM, 2018, 20 (02) :409-418
[8]   Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials [J].
Geiser, Jeanne S. ;
Heathman, Michael A. ;
Cui, Xuewei ;
Martin, Jennifer ;
Loghin, Corina ;
Chien, Jenny Y. ;
de la Pea, Amparo .
CLINICAL PHARMACOKINETICS, 2016, 55 (05) :625-634
[9]   Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index [J].
Gentilella, Raffaella ;
Sesti, Giorgio ;
Vazquez, Luis ;
Sapin, Helene ;
Reed, Victoria ;
Romera, Irene ;
Pozzilli, Paolo .
DIABETES OBESITY & METABOLISM, 2019, 21 (12) :2660-2666
[10]   Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment [J].
Hamano, Kumiko ;
Nishiyama, Hiroshi ;
Matsui, Akiko ;
Sato, Manaka ;
Takeuchi, Masakazu .
ENDOCRINE JOURNAL, 2017, 64 (04) :449-456